Suppr超能文献

抗凝血酶III在体外调节补体活性。

Antithrombin III regulates complement activity in vitro.

作者信息

Weiler J M, Linhardt R J

机构信息

Iowa City VA Medical Center, IA.

出版信息

J Immunol. 1991 Jun 1;146(11):3889-94.

PMID:2033259
Abstract

Heparin, a polyion, exerts its main activity to inhibit coagulation through a serine protease inhibitor, antithrombin III. Previous studies have clearly shown that heparin in the absence of antithrombin III also has the capacity to regulate C activity. The present studies examined the ability of purified human antithrombin III to regulate classical and alternative pathways of C, alone and in the presence of heparin. Antithrombin III alone inhibited generation of both pathways in a dose-related manner; antithrombin III at 8 micrograms/10(7) cellular intermediates inhibited generation of the classical and alternative pathway convertases by 60 and 42%, respectively. Antithrombin III and heparin augmented each other's capacity to inhibit generation of both convertases in a dose-related manner. Antithrombin III did not appear to inhibit on the basis of charge because it is only slightly anionic (isoelectric pH value, 5.0); instead, antithrombin III may have acted as a serine protease inhibitor of the proteolytic enzymes of the C cascades. Antithrombin III acted only to inhibit formation of the alternative pathway convertase but had no activity on terminal lysis by this pathway; similarly, antithrombin III inhibited preformed EAC1,4b,2a,3b but had no activity on classical pathway cellular intermediates containing additional components. Finally, antithrombin III inhibited consumption of factor B hemolytic activity in a reaction mixture that also contained factor D and C3b, suggesting that factor D activity was also inhibited. These studies demonstrate the capacity of antithrombin III to regulate C and suggest that, in concert with heparin, antithrombin III may play an important role in the regulation of C in vivo.

摘要

肝素是一种多聚离子,它通过丝氨酸蛋白酶抑制剂抗凝血酶III发挥其抑制凝血的主要活性。先前的研究清楚地表明,在没有抗凝血酶III的情况下,肝素也有调节补体(C)活性的能力。本研究检测了纯化的人抗凝血酶III单独以及在肝素存在的情况下调节补体经典途径和替代途径的能力。单独的抗凝血酶III以剂量相关的方式抑制两条途径的激活;8微克/10⁷个细胞中间体的抗凝血酶III分别抑制经典途径和替代途径转化酶的激活60%和42%。抗凝血酶III和肝素以剂量相关的方式增强彼此抑制两种转化酶激活的能力。抗凝血酶III似乎不是基于电荷进行抑制,因为它只是略带阴离子性(等电pH值为5.0);相反,抗凝血酶III可能作为补体级联反应中蛋白水解酶的丝氨酸蛋白酶抑制剂发挥作用。抗凝血酶III仅作用于抑制替代途径转化酶的形成,但对该途径的终末溶解无活性;同样,抗凝血酶III抑制预先形成的EAC1,4b,2a,3b,但对含有其他成分的经典途径细胞中间体无活性。最后,抗凝血酶III在也含有因子D和C3b的反应混合物中抑制因子B溶血活性的消耗,表明因子D的活性也受到抑制。这些研究证明了抗凝血酶III调节补体的能力,并表明与肝素协同作用时,抗凝血酶III可能在体内补体调节中起重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验